Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Final lines from the Canaccord report on today's news

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Mar 24, 2021 4:13pm

74 Views

Post# 32868750

RE:Final lines from the Canaccord report on today's news

This is great right? Sure he's still wearing out the W.A.I.T. buttons on his laptop but the dam is showing further signs of breaking.

SPCEO1 wrote:

While we do not currently include the SORT1+ program in our financial model, we

believe this program has the potential to become a significant part of our THTX

investment thesis. We believe there is strong scientific evidence supporting the potential

success of the program and eagerly await initial clinical proof-of-concept from this Phase

I trial.